Express Pharma
Home  »  Latest Updates  »  DRL launches Bivalirudin injection in US market

DRL launches Bivalirudin injection in US market

9

The injection in 250 mg/vial are available in packages of 10 single-dose vials

Dr Reddy’s Laboratories has launched Bivalirudin injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax (Bivalirudin) for Injection, approved by the US Food and Drug Administration (US FDA).

The Angiomax brand and generic had US sales of approximately $198 million MAT for the most recent twelve months ending in March 2017 according to IMS Health.

Dr Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials.

Angiomax is a registered trademark of The Medicines Company.

Comments are closed.